Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Magnolia Neurosciences

Request full access

Drug discovery and development company for neuroprotective medicines

New York City, United StatesFounded 2018Biotech & Life Sciences

About Magnolia Neurosciences

Magnolia Neurosciences Corporation was a biotechnology firm established to develop a new class of neuroprotective medicines aimed at treating neurodegenerative diseases and neuronal injuries. The company was co-founded in August 2018 by life science investment firm Accelerator Life Science Partners and The University of Texas MD Anderson Cancer Center. The scientific foundation for Magnolia stemmed from discoveries made by researchers within MD Anderson's Therapeutics Discovery division, including Philip Jones and Jim Ray. Their research into chemotherapy-induced conditions like peripheral neuropathy and "chemo brain" revealed that the underlying mechanisms of neurodegeneration were common to chronic diseases such as Alzheimer's and Parkinson's.

The company launched with a significant $31 million Series A financing round, attracting investment from a syndicate of prominent venture capital firms and corporate venture arms of major pharmaceutical companies. Investors included AbbVie Ventures, ARCH Venture Partners, Eli Lilly and Company, Johnson & Johnson Innovation, and Pfizer Ventures, among others. The company's strategy focused on developing drug-like small molecules that could block specific components of programmed cell death, a process that becomes reactivated in certain neurological conditions. The goal was to create therapies that could slow or halt neuronal loss, preserving brain tissue and function. Magnolia aimed to rapidly advance these therapies into clinical proof-of-concept for conditions with high unmet patient needs.

The business operated as a drug discovery and development company, with its headquarters in New York City and a subsidiary, Magnolia Tejas Corporation, in Houston, Texas. Its business model was centered on translating preclinical research into commercially viable therapeutics for serious Central Nervous System (CNS) diseases. While the company generated significant initial interest and funding, public information about its progress ceased after its initial launch phase, and its corporate website is no longer active as of early 2024.

Source: Dealroom company data

At a glance

Status
Operational
Employees
1
Open positions
None listed
Dealroom signal
22.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Oncology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCEquity / VC Jul 2020 $5M $20M Undisclosed —
SERIES A✓Equity / VC Aug 2018 $31M $124M ARCH Venture Partners · Eli Lilly · Pfizer · Abbvie Biotech Ventures ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Magnolia Neurosciences website traffic

Latest recorded traffic for Magnolia Neurosciences is 240 monthly website visits, down 7.7% over the last three months. Magnolia Neurosciences's team grew 0% over the past year.

Latest monthly visits240 3-month web change-7.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Tevogen BioClinical-stage specialty immunotherapy company leveraging ExacTcellTM technology platform to harness the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders Metuchen, United States Operational 27 $24M $1.2B
CSPC Pharmaceutical GroupCSPC Pharmaceutical Group is a pharmaceutical group in China Shijiazhuang, China Operational
Transcell BiologicsDiscovery and development of targeted options to cure Cancers and Neurological ailments Hyderabad, India Operational
Navinata HealthNavinata Health is conveniently educating today's busy Physicians about innovative life-saving Therapies Princeton, United States Operational
X4 PharmaceuticalsClinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment Cambridge, United States Operational
Skyhawk TherapeuticsA drug discovery and development company focused on revolutionizing disease treatment with small molecules that correct RNA expression Waltham, United States Operational
Orbus TherapeuticsOrbus Therapeutics is dedicated to developing products that treat rare diseases Palo Alto, United States Operational
Reverie LabsReverie Labs (YC W18) optimizes potential medicines using machine learning Cambridge, United States Acquired
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Magnolia Neurosciences in the New York City ecosystem

Live from Dealroom

The Magnolia Neurosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Accelerator Life Science Partners
  • ARCH Venture Partners
  • Eli Lilly
  • Pfizer
  • Abbvie Biotech Ventures
  • Alexandria Venture Investments
  • Partnership Fund for New York City
  • Johnson & Johnson Innovation

Other known investors1 additional known investor

  • 180 Degree Capital
Employees 1 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Magnolia Neurosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Magnolia Neurosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.